Intraplaque Hemorrhage
Intraplaque hemorrhage (IPH) drives atherosclerosis partly via the dual metabolic insult of cholesterol-enriched erythrocyte membranes and pro-oxidant heme/iron. 1 Indeed, IPH may acutely destabilize coronary lesions causing myocardial ischemia. 2 We have recently shown that IPH generates a distinct adaptive macrophage state (Mhem) in human plaques. 3 We went on to identify activating transcription factor 1 (ATF1) as the key transcription factor mediating adaptive responses to heme at 10 μmol/L, a pathophysiologically relevant concentration. 4 Others have independently designated a similar macrophage phenotype as M(Hb). 5 Mhem exhibit coordinated properties including increased heme oxygenase (HO)-1 expression, reduced oxidative stress, suppressed inflammatory activation, increased lipid export and resistance to foam-cell formation, and increased levels of the anti-inflammatory cytokine interleukin-10. 3 Taken together, these may inhibit atherogenesis if they also apply in vivo. Coinduction of the genes for HO-1 and liver X receptor (LXR) is a key component of ATF1 transcriptional network driving macrophages to become Mhem. 4 coronary artery disease, consistent with a role in responding to IPH in vivo. Both CREB1 and ATF1 are phosphorylated on homologous motifs by cAMP-dependent protein kinase (protein kinase A) and 5′-AMP-activated protein kinase (AMPK). 7, 8 We have previously demonstrated that heme induces ATF1 at both mRNA and protein levels, and causes its activation by Ser63 phosphorylation. 4 The coregulation of HO-1 and LXRβ by phospho-ATF1 allows ATF1 to play a pivotal role in linking storage of iron with export of lipid. Because ATF1 directs these 2 key protective systems to work in concert, it holds enormous therapeutic promise. 9,10 Therefore, we asked which kinases phosphorylate (and thereby activate) ATF1 in response to heme.
5′-AMP-Activated Protein Kinase (AMPK)
AMPK is a key mediator of cellular energy homeostasis and responses to metabolic stress. 11, 12 When activated by low energy levels (low ATP/AMP ratio), it promotes ATP-creating catabolic pathways more than ATP-expending anabolic pathways. 11, 12 It is also activated by oxidative or genotoxic stress. 11 Structurally, AMPK is composed of 3 chains (α,β,γ), each with up to 3 isoforms. 13 AMPK may modify transcription via phosphorylation of a large and growing number of transcription factors and chromatin proteins. 12, [14] [15] [16] [17] [18] [19] [20] Critically, these include ATF1. 8 Purified AMPK phosphorylated recombinant purified ATF1 in an in vitro kinase assay in a cell-free system, in an article defining AMPK-mediated phosphorylation of CREB-family proteins in vivo in skeletal muscle during exercise. 21 Moreover, AMPK activation in macrophages induces an anti-inflammatory response, with release of interleukin-10. 22 Thus, AMPK is a strong candidate to mediate ATF1 phosphorylation and transcription in response to heme after IPH and erythrophagocytosis.
Metformin
Metformin is effective in Type-II diabetes mellitus, 23, 24 without causing hypoglycemia. Indeed, metformin has proven sufficiently safe more than ≈50 years that it is now prescribed for debilitating but nonlife-threatening endocrine disease and metabolic syndrome. 25, 26 In 2 independent, recent, large-scale, clinical trials, metformin has exhibited a significantly greater reduction of cardiovascular events (which are mainly attributable to atherosclerosis) than would be expected from the improved glycemic control alone. 27 This suggests that metformin may have a direct vascular protective effect, possibly located in the vessel wall.
AMPK is also known to be activated by metformin. 25 However, although metformin clearly can activate AMPK, it is not clear how much of its clinical effect critically requires AMPK versus other pathways. 28, 29 Interestingly, there is some evidence that AMPK may be anti-inflammatory in classical T-lymphocyte/macrophage-mediated inflammation models such as extrinsic allergic encephalomyelitis. 30 This raises the possibility that metformin may have wider potential as an anti-inflammatory agent in classical inflammatory diseases such as transplant rejection and autoimmunity, as well as in atherosclerotic inflammation. 30
Hypothesis and Summary
We tested the hypothesis that an AMPK-ATF1 pathway mediates heme-induced HO-1 and LXRβ and examined the implications for potential mechanisms of action of metformin. We show here that heme at a pathophysiologically relevant concentration (10 μmol/L) 4 and metformin at a pharmacologically relevant concentration (also 10 μmol/L) 31 increase ATF1 transcripts, ATF1 protein, and activated (phospho-Ser63) ATF1, via AMPK, and that thereby metformin induces ATF1-dependent pathways including HO-1 and LXRβ. Thus, AMPK is a key initiator of ATF1 signaling evoked by IPH, and AMPK-mediated ATF1 activation may be therapeutically activated by metformin.
Materials and Methods
Materials and Methods are available in the online-only Supplement. We cultured human blood-derived macrophages from normal human volunteers, with ethical approval and informed consent; and monocyte purification was as we previously described. 3 We used established transfection methods for small inhibitory ribonucleic acid (siRNA) and plasmids to obtain molecular specificity, supplemented with pharmacological reagents. Mouse bone marrow-derived macrophages (BMM) were cultured as widely established. Cell culture, RNA analysis, and Western blotting were performed as before. 4
Results

Heme Activates AMPK in Human Blood-Derived and Plaque Macrophages
AMPK has a catalytic α subunit that can be activated by autophosphorylation, with -α1 being the main α chain in human macrophages. We probed lysates of human macrophages by immunoblotting with antiphospho-AMPK-α1. We found that heme (10 μmol/L) increased (activated) phospho-AMPK, in a biphasic pattern, with an initial peak within minutes and a later one at 2 to 4 hours coincident with the p-ATF1 ( Figure 1A ). At this pathologically relevant concentration, heme induced ATF1 protein progressively during 4 hours; phospho-ATF1 during 0.125 to 4 hours; and HO-1 target protein at 4 hours ( Figure 1A) . Thus, the timing of AMPK activation by heme was sufficiently early to be consistent with an initiating event. Next, we assessed the in vivo relevance of AMPK by performing confocal microscopy of human plaques ( Figure 1B ). We found that phospho-AMPK was expressed by Mhem macrophages in areas of IPH, but not control foamcell areas, identified by comparison with serial sections that had been immunostained for p-ATF1, HO-1, LXR, ABCA-1, 8-oxo-G, CD163, and human leukocyte antigen type DR in previous publications ( 3, 4 and data not shown). We have previously shown that p-ATF1 is a key functional and immunohistochemical identifier of Mhem because it directs the majority Nonstandard Abbreviations and Acronyms ATF1 activating transcription factor 1 AMPK 5′-AMP-activated protein kinase HO-1 heme oxygenase-1
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WT wild type November 2013 of heme-induced genes and is found selectively in Mhem cells in plaques. 4 The sections were therefore also double stained for p-ATF1 and p-AMPK, which indeed showed colocalization in the same cells ( Figure 1B ). As might be expected, p-AMPK was predominantly in the cytoplasm, and p-ATF1 was predominantly in the nucleus ( Figure 1B ).
Pharmacological Inhibition of AMPK Inhibits Induction of Phospho-ATF1, ATF1, HO-1, and LXRβ by Heme and Metformin
Because heme (10 μmol/L) activated AMPK and ATF1, we next determined whether there was a causal connection, initially using a simple pharmacological strategy and protein quantification by Western analysis (representative blots in Figure 2A , densitometry in Figure 2B ). We found that metformin at 10 μmol/L (a known AMPK activator) induced phospho-ATF1, and its target genes HO-1 and LXR; and that these activation events in response to either heme (10 μmol/L) or metformin (10 μmol/L) were antagonized by 1 μmol/L compound-C (dorsomorphin), a known inhibitor of AMPK (Figure 2A and 2B). Then, we assessed whether the induction of target proteins by metformin was via mRNA (ie, transcriptional; Figure I in the online-only Data Supplement). We found that metformin induced mRNA for ATF1 ( Figure IA and IB in the onlineonly Data Supplement), followed by that for HO-1 ( Figure Then, they were cultured with heme (10 μmol/L), metformin (10 μmol/L), the AMPK-inhibitor compound-C (dorsomorphin 1 μmol/L), and protein lysates were made at 4 hours. Lysates were run on SDS-PAGE, electrotransferred to polyvinyldifluoride membranes, which were immunoblotted with antibodies to phospho-ATF1, total ATF1, phospho-ACC, HO-1, and LXRβ as indicated (Methods LXRβ, and induction of each was inhibited by the specific AMPK-inhibitor compound-C (dorsomorphin) at 1 μmol/L ( Figure IB , ID, and IE in the online-only Data Supplement). Thus, heme and metformin induce ATF1, HO-1, and LXRβ via an AMPK-dependent transcriptional pathway.
AMPK-Knockdown Inhibits Induction of Phospho-ATF1, HO-1, and LXR by Heme and Metformin
To show that heme and metformin specifically activated ATF1 via AMPK, we next corroborated the pharmacological inhibition with an siRNA approach, using transfection protocols that we have validated for human blood-derived macrophages ( Figure 3 ). Heme (10 μmol/L) induced phospho-ATF1, and this was suppressed by AMPK-α1 knockdown by siRNA, with oligos from Qiagen ( Figure 3A and 3C). These data were extended and corroborated with siRNA oligos from an independent supplier (namely Dharmacon), individually targetting each subunit of AMPK that had been identified as expressed in macrophages by microarray 4 ( Figure II in the online-only Data Supplement).
These experiments showed that the stimulants heme and metformin (10 μmol/L each; Figure II in the online-only Data Supplement) induced phospho-ATF1, and in each case phospho-ATF1 induction was inhibited by AMPK-knockdown, to variable degrees depending on which individual AMPK subunit was suppressed. Then, we examined the effects of suppressing each of the AMPK subunits, and of all of the AMPK subunits together, again using siRNA transfection in primary human macrophages ( Figure III in the online-only Data Supplement). This combined AMPK-knockdown suppressed AMPK, which inhibited the capacity of heme (10 μmol/L) to increase phospho-ATF1, HO-1, and LXRβ proteins (quantified by densitometry in Figure III in the online-only Data Supplement). Then, we performed essentially the same procedure for metformin ( Figure 3B and 3D). Metformin (10 μmol/L) induced each of p-ATF1, p-AMPK, HO-1, and LXRβ, and the induction of each of these was suppressed by AMPK-knockdown ( Figure 3B and 3D).
Then, we examined the AMPK-dependence of key hememodulated macrophage functions that were potentially
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Control-siRNA AMPK-α1-siRNA therapeutic. 4 We found that AMPK-knockdown caused heme (10 μmol/L) to become pro-oxidant ( Figure 4A ); prevented the cholesterol export induced by heme (10 μmol/L; Figure 4B ); reversed suppression of cholesterol accumulation caused by heme (10 μmol/L; Figure 4C ); and prevented heme from inducing interleukin-10 secretion ( Figure 4D ). Although heme suppresses foam-cell formation, heme in fact promoted uptake of di-O-labeled oxidized low density liporoteins (LDL), indicating that it does not prevent phagocytic clearance of extracellular oxidized LDL ( Figure 4E ). AMPK-knockdown and ATF1-knockdown inhibited this effect ( Figure 4E ).
Beta (β)-Oxidation Pathway of Cellular Lipid Disposal Is Activated by Heme via AMPK and ATF1
Our microarray data on heme-stimulated macrophages identified induction of multiple β-oxidation genes, one of the principal pathways for fatty acid degradation. 4 Human blood-derived macrophages were cultured with a combined-AMPK-siRNA protocol (Methods). Then, heme (10 μmol/L) was added for a further 24 hours, and highly reactive oxygen species (peroxynitrite, hypochlorite, hydroxyl radicals) were measured using aminophenylfluorescein dye as before. 4 *P<0.05, Student t test, AMPK-knockdown by combined-siRNA reverses heme-mediated hROS suppression (note that in the absence of double-stranded RNA, heme is normally outright antioxidant). B, AMPK-dependence of induction of cholesterol export by heme. Human blood-derived macrophages were cultured with a combined-AMPK-siRNA protocol (Methods). Then, heme (10 μmol/L) was added for a further 24 hours, and the medium was changed, and then cholesterol was exported to supernatant containing lipoprotein-free fetal calf serum and 10 μg·mL −1 ApoA1 (both Sigma-Aldrich), using an ultrasensitive enzymatic assay based on cholesterol oxidase and Amplex Red as before. 4 *P<0.05, Student t test, AMPK-siRNA reverses heme-induced cholesterol export, n=5 donors. C, AMPK-dependence suppression of cholesterol accumulation by heme. Human blood-derived macrophages were cultured with a combined-AMPK-siRNA protocol (Methods). Then, heme (10 μmol/L) was added to the culture medium, along with 30 μg·mL −1 oxidized low density lipoproteins (OxLDL). Supernatant and cellassociated cholesterol were measured with an ultrasensitive enzymatic assay based on cholesterol oxidase and Amplex Red as before. 4 *P<0.05, Student t test, heme suppresses cholesterol accumulation, strongly reversed by AMPK-knockdown by combined-siRNA, n=5 donors. In macrophages with AMPK-knockdown, heme causes an increase in cell cholesterol. D, Interleukin-10 (IL-10) secretion in response to heme is AMPK dependent. Human blood-derived macrophages were cultured with the combined-AMPK-siRNA protocol (Methods). Macrophages were cultured as before in 96-well plates, supernatants were collected and assayed for IL-10 using a DuoSet (R&D Systems). Data are mean±SE, n=5 donors. *P<0.05, Student t test. E, Heme increases OxLDL uptake in an AMPK-dependent and activating transcription factor 1 (ATF1)-dependent manner. Human blood-derived macrophages were cultured with the combined-AMPK-siRNA protocol (Methods). Data are representative flow cytometric histograms n=3 donors. Treatments are as indicated.
nongenomic mechanism involving phosphorylation of acetyl-CoA-carboxylase (ACC). 32 Although LXR directs cholesterol export, its ability to combat lipid overload is blunted by coinduction of the fatty acid synthase (FASN) gene. 10, 33 Thus, coordinated activation of both fatty acid oxidation (regulated by AMPK directly) and cholesterol export (regulated via LXR) is likely to be complementary for foam-cell protection. Therefore, we assessed the role of heme in β-oxidation by accepted methodology, using decay of a fluorescently tagged fatty acid BODIPY-C11 as in Figure IV in the online-only Data Supplement. We found that heme (10 μmol/L) induces the degradation of this fluorescent fatty acid tracer in a timedependent manner, and this was blocked by etomoxir, a specific inhibitor of mitochondrial β-oxidation ( Figure IVA in the online-only Data Supplement). 34 This heme-induced β-oxidation was blocked by ATF1-siRNA ( Figure IVB in the online-only Data Supplement) and by AMPK-knockdown by combined-siRNA ( Figure IVC in the online-only Data Supplement). This indicated that it is dependent on both AMPK and ATF1 consistent with an AMPK-ATF1 pathway. As expected for a known AMPK activator, metformin (10 μmol/L) also induced β-oxidation, which was also blocked by AMPK-knockdown by combined-siRNA ( Figure IVD 
AMPK Activator Metformin Reproduces ATF1 Signaling in Mhem
In normal human volunteers, the peak plasma metformin concentration after oral absorption of a standard prescribed tablet (CP max ) is 10 μmol/L. 31 Figure 5A shows a concentration-effect curve of metformin on the release of highly reactive oxygen species (hROS) from macrophages derived from normal human volunteers, with the peak plasma concentration highlighted. In contrast to simple dihydro-dyes for redox potential, hROS specifically detect the most pathological species (peroxynitrite, hypochlorite, and hydroxyl radicals) via electrophilic adduction of the amino group of the dye aminophenylfluorescein. 35 Notably, substantial antioxidant protection (25%-50%) was identified at the CP max (10 μmol/L) and at considerably lower metformin concentrations than the CP max (100 nmol/L-1 μmol/L).
The suppression of macrophage hROS by metformin at CP max (10 μmol/L) was reversed by AMPK-knockdown by combined-siRNA ( Figure 5B ). We had previously found that heme (10 μmol/L) suppresses the macrophage antigen presentation molecule and activation marker human leukocyte antigen type DR via an ATF1 pathway. Therefore, we examined the effects of metformin on macrophage human leukocyte antigen type DR, finding that 10 μmol/L metformin substantially suppressed surface human leukocyte antigen type DR on macrophages ( Figure 5C ).
Next, because we had shown that 10 μmol/L metformin also induced LXRβ mRNA and protein, we assessed whether this had resultant beneficial effects on lipid metabolism. We found that metformin prevented foam-cell formation attributable to incubation with oxidized LDL in 5 separate macrophage cultures from normal volunteers ( Figure 5D ), as previously published with heme (10 μmol/L). 4 We next analyzed the mechanism of this effect with the AMPK-knockdown by combined-siRNA protocols used in preceding experiments, quantifying foam-cell formation as published ( Figure 5E ). Both 10 μmol/L heme and 10 μmol/L metformin suppressed oxidized LDL-induced foam-cell formation; and both effects were prevented with AMPK-knockdown by combined-siRNA ( Figure 5E ). Then, we corroborated this effect by analyzing cellular cholesterol, and showed that this effect of metformin was AMPK dependent because it was abolished by AMPKknockdown by combined-siRNA ( Figure 5F ). We have previously validated an ApoA1-dependent export assay that measures the LXR/ABCA1 pathway. 4 Macrophage cholesterol export to ApoA1 in the culture medium was stimulated by metformin in macrophages from 5 normal human volunteers and prevented by AMPK-knockdown by combined-siRNA ( Figure 5G ). Thus, metformin reproduces multiple potentially therapeutic features of the effect of heme on macrophages, and both do so in an AMPK-dependent and ATF1-dependent pathway.
Heme and Metformin Induce Less p-ATF1, HO-1, and LXR in AMPK-KO Compared With Wild-Type Murine Bone Marrow Macrophages
In human blood-derived macrophages, which are highly relevant, AMPK-knockdown reduced the ability of heme and metformin to activate p-ATF1, HO-1, and LXRβ and promote linked antioxidant and foam-cell protective effects. However, because these were knockdown experiments, we wished to identify the precise contribution of AMPKdependent and AMPK-independent pathways by using formal knockouts. Therefore, we assessed responses to heme and metformin in bone marrow macrophages (BMMs) from AMPK-knockout (AMPK-KO) and matched wild-type (WT) mice ( Figure 6 ).
In WT BMMs, heme (10 μmol/L) activated pThr172-AMPK, with subsequent induction of pSer63-ATF1, t-ATF1, HO-1, and LXRβ (n= 10 mice; Figure 6A ). This was less apparent in BMMs from AMPK-KO mice ( Figure 6A ). As controls, AMPK was absent in AMPK-KO mice, as was AMPK activation ( Figure 6A ). In WT BMMs, metformin (100 μmol/L) activated pT172-AMPK, with subsequent activation of pSer63-ATF1, t-ATF1, HO-1, and LXRβ (n= 10 mice; Figure 6B ). This was less apparent in BMMs from AMPK-KO mice ( Figure 6B ). Thus, in murine BMMs, heme and metformin activate the same ATF1/HO-1/LXR cascade that they do in human, and the activation is dependent on AMPK.
The functional consequences of this activation were next tested ( Figure 6C-6F) . In WT BMMs, incubation with heme (10 μmol/L) for 48 hours suppressed oxidative stress as measured by aminophenylfluorescein, which detects highly reactive oxygen species ( Figure 6C ). In contrast, in BMMs from AMPK-KO mice, heme and metformin had the opposite effect, increasing hROS ( Figure 6C) . A similar mechanism was found with metformin ( Figure 6D ). In WT BMMs, incubation with metformin (10 μmol/L) for 48 hours suppressed oxidative stress as measured by aminophenylfluorescein, which detects highly reactive oxygen species ( Figure 6D ). In contrast, in BMMs from AMPK-KO mice, heme and metformin had the opposite effect, increasing hROS ( Figure 6D ). Human blood-derived macrophages were cultured with increasing concentrations of metformin, and oxidative stress was measured as highly reactive oxygen species after 48 hours (peroxynitrite, hypochlorite, hydroxyl radicals) with aminophenylfluorescein (APF) as before. 4 Red box indicates peak plasma concentration after oral dose (10 μmol/L). Data are mean±SE. *P<0.05, Student t test, n=5 independent experiments. B, AMPK-dependence of suppression of oxidative stress by metformin. Human blood-derived macrophages were transfected with control-siRNA oligos or combined-AMPK-siRNA oligos as indicated; using the protocol validated in Figure 3 . Then, the cells were cultured in the presence or absence of metformin for a further 24 hours, and oxidative stress was measured using APF as in Figure 6A . Data are mean±SE. *P<0.05, Student t test, n=5 independent experiments. C, Metformin suppresses activation marker human leukocyte antigen type DR (HLA-DR) in human blood-derived macrophages at clinically relevant concentrations. Human blood-derived macrophages were cultured in the presence or absence of 10 μmol/L metformin as indicated; macrophages were harvested after 4 days of culture, and fluorescently stained for HLA-DR and analyzed by flow cytometry. Representative of n=3 donors. D, Metformin suppresses foam-cell formation in human blood-derived macrophages at clinically relevant concentrations. Human blood-derived macrophages were cultured in the presence or absence of 10 μmol/L metformin (bottom) and 30 μg·mL −1 oxidized low density lipoproteins (OxLDL; right) for 1 week and then fluorescently stained for lipid with Nile Red and counterstained with a nuclear counterstain. Metformin prevents OxLDL-induced foam-cell formation. Image representative of n=5 donors. (green=completely neutral lipid, eg, triglyceride; yellow=mildly polar lipids, eg, phospholipid; red=TOPRO nuclear dye). E, Metformin suppresses foam-cell formation in human blood-derived macrophages via AMPK. Human bloodderived macrophages (n=5 donors) were cultured in the presence or absence of 10 μmol/L metformin, 10 μmol/L heme, and 30 μg·mL −1 OxLDL for 1 week, as in D, and also in the presence of AMPK-knockdown by combined AMPK-αβγ siRNA or matched pooled control-siRNA as indicated. Cells were fluorescently stained for lipid as in D and analyzed by counting foam cells with a confocal microscope as before. 4 *P<0.05, ANOVA, metformin, and heme suppress OxLDL-induced foam-cell formation prevented by AMPK-knockdown by combined-siRNA. Note, heme had no significant effect on foam-cell formation in the absence of OxLDL feeding, a control that is already published and omitted in the interests of space and duplication. 4 Data are mean±SE, n=9 donors. *P<0.05, Student t test. F, Metformin increases cholesterol export to HDL via AMPK. Human blood-derived macrophages were cultured in the presence or absence of 10 μmol/L metformin, the medium was changed and then cholesterol exported to supernatant containing lipoprotein-free fetal calf serum and 10 μg·mL −1 ApoA1 (both Sigma-Aldrich). Cholesterol in the cells and supernatant were compared using an ultrasensitive enzymatic assay based on cholesterol oxidase and Amplex Red as before. 4 *P<0.05, metformin induces total cell cholesterol export to ApoA1 (forming HDL), prevented AMPK-knockdown by combined-siRNA. G, Metformin decreases human blood-derived macrophage cholesterol content via AMPK. Human blood-derived macrophages were cultured in the presence or absence of 10 μmol/L metformin and 30 μg·mL 1 OxLDL for 1 week, in the presence of AMPKknockdown by AMPK-αβγ siRNA or matched control-siRNA as indicated. Then, cholesterol was assessed in lysates using an ultrasensitive enzymatic assay based on cholesterol oxidase and Amplex Red as before. 4 Metformin reduces total cell cholesterol accumulation, prevented by AMPK-knockdown by combined-siRNA. Data are mean±SE. *P<0.05, Student t test. Next, the effects of heme and metformin on survival of WT and AMPK-KO BMMs were assessed, using the XTT vital dye. This revealed an effect converse to that on oxidative stress, that is heme or metformin increased survival in WT cells but reduced survival in AMPK-KO cells ( Figure 6E ).
Then, we studied the resistance of WT and AMPK-KO murine BMMs to lipid accumulation (foam-cell formation; Figure 6E ). Oxidatively modified LDL evoked formation of foam cells (as with human macrophages; Figure 6F ). Heme (10 μmol/L) and metformin (10 μmol/L) also suppressed foam-cell formation ( Figure 6F ; as with human macrophages). Protection from foam-cell formation by either heme or metformin was lost in AMPK-KO BMMs (akin to AMPKknockdown in human macrophages; Figure 6F ). Thus, we have previously shown that the transcription factor ATF1 is a key mediator of development of the Mhem phenotype in human atherosclerotic plaques. 4 Here, we show that heme and metformin activate ATF1 via AMPK in both human and murine cells in vitro, with transcriptional induction of HO-1 and LXR that allows interlinking of antioxidant activity and resistance to foam-cell formation.
Discussion Summary
We show here that ATF1, which we previously established, is the key driver of Mhem macrophages and is activated by heme (10 μmol/L) via AMPK-dependent phosphorylation. We have defined a clinical application of this pathway, in which metformin, a common safe oral hypoglycemic agent, may coregulate anti-inflammatory, antioxidant, and foam-cell protective mechanisms in macrophages. Therefore, the data are highly significant for clinical treatment of atherosclerotic risk, and potentially inflammation in general.
AMPK and Metabolic Stress
Although AMPK is primarily a responder to low fuel, [36] [37] [38] it is also a wider stress-activated kinase, being also activated by oxidative stress, osmotic stress, 39 ionizing radiation, 40 and hypoxia, 41 and may therefore play a role in signaling akin to classical stress-activated protein kinases such as p38MAPK and jun N-terminal kinase. We suggest that the metabolic stress of erythophagocytosis parallels that of energy deprivation because both are associated with oxidative stress and require activation of catabolic pathways. Indeed, the term heme stress may be appropriate.
AMPK and Macrophage Phenotype
It was previously shown that transfecting a mouse macrophage cell line with expression plasmids for constitutively active AMPK modified macrophage signaling, increasing phospho-CREB, increasing phospho-PI3K, and suppressing phospho-IκBα; together with induction of interleukin-10 and suppression of tumor necrosis factor-α. 22 The converse was obtained with dominant negative AMPK. 22 Moreoever, a classical anti-inflammatory stimulus promoted AMPK phosphorylation and induced AMPK, whereas (bacterial) lipopolysaccharide (a classical inflammatory stimulus) had the reverse effect. 22 We now extend these data and translate them to metformin pharmacology.
ATF1 and Stress Kinases Other Than AMPK
ATF1 is phosphorylated by several stress kinases including AMPK in skeletal muscle during exercise, 21 p38MAPK in leptin signaling, 42 mitogen-stimulated kinase in UV-induced stress, 43, 44 and by protein kinase D. 45 Tyrosine phosphorylation of ATF1 by homeodomain interacting protein kinase 2 has also been described in response to genotoxic stress. 46 Understanding the full role of AMPK/ATF1 in the context of other upstream kinases regulation in the differentiation of Mhem is a major priority for further work. A combinatorial role of alternative kinases seems possible because there were subtle mismatches between increases in phospho-ATF1 and in the target genes.
AMPK and TFs Other Than ATF1
Although AMPK was first, and best, characterized as a posttranslational regulator of metabolic enzymes, recent work reveals that it has important and numerous transcriptional effects (ie, mediated by phosphorylation of transcription factors). 13, 17 Indeed, there is a described AICAR-response element and corresponding AICAR-response element binding protein, which is a zinc-finger protein. 47 AMPK mediates in vitro and in vivo phosphorylation of CREB-family proteins in skeletal muscle in exercise, and in the same article was shown to direct phosphorylation of purified ATF1 by purified AMPK in a cell-free system. 21 The functional consequences are potentially profound because microarray-validated target genes for AMPK, modulated in skeletal muscle in AMPK-KO mice in vivo include phosphoenol pyruvate carboxykinase (the rate limiting enzyme for gluconeogenesis), fatty acid synthase (the rate limiting enzyme for fatty acyl/triglyceride production), eNOS (the endothelial cytoprotective vasodilator), ferritin (which safely stores iron), d-amino-levulinic acid synthase (d-ALA-synthetase, ALAS, the enzyme for the rate limiting step of heme biosynthesis). 48 Thus, AMPK regulate genes controlling vascular tone, iron storage, porphyrin/heme biosynthesis in addition to its traditional roles in glucose metabolism. 48 Moreover, AMPK may inactivate NF-κB 49 and suppresses oxidative stress via upregulation of thioredoxin. 50 Given the anti-inflammatory effects of AMPK, and its direction of a plethora of protective transcriptional effects, it is plausible that AMPK might initiate commitment to Mhem. Of interest, we found by systems biology approaches that the heme-induced geneset was enriched in ChIP-Seq validated binding sites for ≈7 TFs, which in turn contained conserved AMPK-phosphorylation motifs (not shown).
Metformin and AMPK-Dependence
The mechanism of action of metformin is still in the process of elucidation. 25 Some data, using the small molecule AMPK-inhibitor dorsomorphin, indicated that the hypoglycemic effects of metformin may be largely AMPK mediated. 51 Metformin-mediated activation was also found to be dependent on the tumor-suppressor gene liver kinase B (LKB), which is often taken as an exclusive upstream kinase of AMPK. 52 More recently, doubt was thrown on the specificity of metformin for AMPK because many of its hepatic hypoglycemic effects are identical in AMPK-knockout mice. 29 In this article, we carefully showed AMPK-dependence of the effects of metformin in human primary macrophages in vitro, using corroborating siRNA transfection and pharmacological strategies.
Possible Clinical Applications
Metformin is a relatively safe oral hypoglycemic agent that, unlike sulfonylureas, does not provoke hypoglycemia, even in normoglycemic subjects or in overdose. 26 This is thought to be related to its activation of cellular energy homeostasis. 26 In 2, recent, large-scale, clinical trials of cardiovascular end points in diabetes mellitus, metformin had a greater reduction in cardiovascular events than was predicted from its effects on glycemic control alone. 27 This suggested the possibility of a putative direct effect on vessels. 53 Other studies have suggested variable but favorable effects on lipid profile, with reduced LDL in diabetes mellitus 27, 54 or enhanced high density lipoprotein in polycystic ovarian syndrome. 27, 55 These findings provide a potential mechanism for these clinical effects. Namely, metformin may direct a major pathogenic cell type in atherosclerotic lesions to initiate joint antioxidant, anti-inflammatory and cytoprotection, with promotion of cholesterol efflux to high density lipoprotein. Metformin may therefore be an agent that could suppress atherosclerotic plaque inflammation useful in a wider range of risk factors than in solely overt diabetes mellitus. Moreover, because there is evidence that metformin is also cardioprotective by improving myocardial remodeling and myocardial protection in ischemia-reperfusion, 27 this may reflect commitment to Mhem macrophages in damaged myocardium. Our work is yet limited by being restricted to in vitro macrophage, albeit human monocyte-derived macrophages from multiple normal volunteers. Taking the work further will require progression to in vivo models such as low density lipoprotein receptor −/− , ATF1 −/− , and AMPK −/− mice. Moreover, pigs readily develop vascular and cardiometabolic disease in response to diet, like humans, and would make a representative model. Finally, analyzing peripheral blood monocytes in patients before and after metformin commencement would yield insights into the clinical relevance. In vivo and transcriptomic studies are now urgently required to define potential therapeutic implications and these are planned.
Conclusions
Here, we show that heme and metformin activate ATF1 via AMPK in both human and murine cells in vitro. The AMPK-ATF1 pathway drives transcriptional coinduction of HO-1 and LXR that allows interlinking of antioxidant activity, resistance to foam-cell formation, and macrophage deactivation. We have previously identified that ATF1 initiates a coordinated transcriptional response and macrophage phenotype that we termed Mhem. Because metformin is an important antidiabetic drug, these data yield a new mechanistic insight into recent clinical trial data, indicating an enhanced suppression of diabetic macrovascular disease by metformin. Whether this pathway protects against vascular disease in vivo is under active investigation.
